[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49

Advertisement
4. Baba K, Yajima M, Iwamoto T, Minagawa N, Kazama A: [Testicular malignant lymphoma: report of two cases]. Hinyokika Kiyo; 2001 Aug;47(8):605-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular malignant lymphoma: report of two cases].
  • Both patients received high orchiectomy under the diagnosis of testicular tumor and the histopathological diagnosis in both patients was non-Hodgkin's lymphoma.
  • Case 1 was diffuse, medium-sized B cell type, and case 2 was diffuse, mixed B cell type.
  • Neither patient received any adjuvant chemotherapy nor postoperative irradiation.
  • In case 2, 2 years and 6 months postoperatively, para-aortic lymph node swelling occurred, and chemotherapy was initiated with THP-COP but the patient died at 3 years and 3 months after high orchiectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Male. Orchiectomy. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579606.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


5. Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer; 2001 Jul 15;92(2):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
  • BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.
  • METHODS: Eligibility criteria included histologically documented, diffuse small cleaved, diffuse mixed, diffuse large cell, or immunoblastic lymphoma, Stage III--IV or bulky Stage II disease, and an ECOG performance status of 0--1.
  • The MTD in both studies was defined as the dose at which 50% of patients had 1) Grade 4 neutropenia or thrombocytopenia lasting 7 days or more, or 2) Grade 3--4 hemorrhage or nonhematologic toxicity (excluding alopecia, nausea, and emesis), or 3) were prevented from receiving 100% of drug on Day 22.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466671.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA45418
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


6. Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ: Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2000;6(5A):555-62
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
  • We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkin's lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT).
  • After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals.
  • Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg per day and leukapheresis upon recovery from white blood cell nadir.
  • The hematopoietic cell product was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and complement.
  • The NHL histologies were diffuse large cell, follicular/diffuse mixed, small noncleaved cell, T-cell-rich B-cell, lymphoblastic, and peripheral T cell.
  • Nine were removed from the study after the first or second phase because of progressive disease (n = 5), poor hematopoietic cell mobilization (n = 1), excessive toxicity (n = 2), and chronic active hepatitis C (n = 1).
  • Treatment-related toxicities in the remaining 11 transplant recipients were cardiomyopathy, hemorrhagic cystitis, persistent cytopenias, acute renal failure, abnormal liver function test results, and infectious complications.
  • There were no treatment-related deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Purging. Hematopoietic Stem Cell Mobilization / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Adult. Bone Marrow Diseases / chemically induced. Cardiomyopathies / chemically induced. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystitis / chemically induced. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug-Induced Liver Injury / etiology. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemorrhage / chemically induced. Humans. Infection. Leucovorin / administration & dosage. Life Tables. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Pilot Projects. Salvage Therapy. Survival Analysis. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11071261.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Apr;37(3-4):351-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
  • The purpose of this study was to develop a model for predicting the occurrence of life-threatening neutropenia (LN, ANC < or = 0.5 x 10(9)/l) and febrile neutropenia (FN, an ANC < 0.5x10(9)/l in association with a body temperature of > or = 38.3 degrees C) after the first cycle of CHOP therapy in patients newly diagnosed with aggressive NHL.
  • One hundred and forty-five patients, aged > or = 15 years, with newly diagnosed diffuse mixed, diffuse large-cell or large-cell immunoblastic lymphoma (IWF categories, F, G, H), who had been treated with CHOP at King Chulalongkorn Memorial Hospital between June 1994 and December 1998, were entered into the study.
  • The criteria for eligibility included complete work-up for baseline evaluation, treatment with standard CHOP chemotherapy, at least one complete blood count performed during days 8-14 post-treatment or if at any time the patients experienced a BT of > or = 38.3 degrees C and were not treated with any colony-stimulating factors (CSFs).
  • Thirty-nine percent of the patients had LN at nadir and 33% developed FN after the first course of CHOP.
  • By using stepwise logistic regression analysis, the pretreatment variables independently predictive of the LN at nadir and the FN were serum albumin concentration of < or = 3.5 g/dl, serum LDH > 1 x normal and whether there was bone marrow involvement of lymphoma at presentation.
  • The model, based on the incorporation of these three factors, identified three risk groups of patients with a predicted probability of developing LN at nadir of 81.5% (95% CI, 68.5-90.7) (high risk), 23.9% (95% CI, 12.6-38.8) (intermediate risk) and 4.4% (95% CI, 0.5-15.1) (low risk).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fever / epidemiology. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10752986.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Akazawa S: [Metachronous bilateral primary malignant lymphoma of the testis: a case report]. Nihon Hinyokika Gakkai Zasshi; 2000 May;91(5):526-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous bilateral primary malignant lymphoma of the testis: a case report].
  • Histological findings revealed non-Hodgkin's lymphoma (NHL) of diffuse, mixed type, B cells.
  • About 3 years and a month earlier, he had undergone right high orchiectomy and postoperative radiotherapy (inverted Y irradiation) and chemotherapy (CHOP 5 cycles) for a right testicular tumor whose histological findings were NHL of diffuse, large cell type, B cells.
  • Metachronous bilateral primary malignant lymphoma of the testis is very rare and we discussed each tumor origin by using IgH gene (IgJHDNA) rearrangement as a tumor specific marker of B cell lineage malignant lymphoma.
  • We discussed the clonality of IgJHDNA rearrangement using polymerase chain reaction (PCR) in each paraffin fragment diagnosed pathologically as NHL of B cell origin.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Second Primary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunoglobulin Heavy Chains / genetics. Male

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10853335.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


9. Bandyopadhyay SK, Dutta S, Dutta A: Panniculitis-like T-cell lymphoma with fatal termination. J Indian Med Assoc; 2005 Oct;103(10):551-2
Genetic Alliance. consumer health - Panniculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panniculitis-like T-cell lymphoma with fatal termination.
  • Three months later, the patient presented with carvical lymphadenopathy and compressive thoracic myelopathy and a diagnosis of diffuse mixed- cell lymphoma was established.
  • Immunohistochemical study of subcutaneous lesions confirmed their T-cell origin.
  • Chemotherapy was started but patient succumbed to his disease.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498764.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Ogino J, Kawakatsu C, Hirasawa A, Sato T, Kawamura S, Nishikawa T, Wakabayashi Y: [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade]. Rinsho Ketsueki; 2001 Nov;42(11):1101-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade].
  • Abdominal ultrasonography and computed tomography revealed bilateral renal tumors.
  • Percutaneous needle biopsy of the left renal tumor was performed, and the final diagnosis was non-Hodgkin's lymphoma (diffuse mixed, B cell type, CSIIA).
  • After six courses of chemotherapy, the tumor lesions were markedly reduced, and at present there is no evidence of recurrence.
  • [MeSH-major] Hematuria / etiology. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808078.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Toyota S, Nakamura N, Dan K: [Coexistence of pure red cell aplasia and autoimmune hemolytic anemia occurring during remission of malignant lymphoma]. Rinsho Ketsueki; 2002 Jun;43(6):493-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Coexistence of pure red cell aplasia and autoimmune hemolytic anemia occurring during remission of malignant lymphoma].
  • A diagnosis of malignant lymphoma (ML) (diffuse mixed, B-cell type) had been made in March 2000 whereafter she had been treated with CHOP chemotherapy and had achieved complete remission (CR).
  • On examination, it was found she had concurrently developed pure red cell aplasia (PRCA) and warm type autoimmune hemolytic anemia (AIHA) without relapse of the ML.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Red-Cell Aplasia, Pure / etiology

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134708.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Deisch J, Fuda FB, Chen W, Karandikar N, Arbini AA, Zhou XJ, Wang HY: Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med; 2009 Sep;133(9):1477-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study.
  • An association between intravascular large B-cell lymphoma (IVLBCL) and the mixed lineage leukemia (MLL) gene has never been demonstrated.
  • Morphologically, the atypical lymphoid infiltrate was entirely confined in the lumina of capillaries, small vessels, and sinusoidal space.
  • Conventional cytogenetic analysis from the bone marrow aspirates displayed a complex karyotype, with a notable triple tandem repeat at band segment q22-q25 of chromosome 11.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Tandem Repeat Sequences / genetics. Trisomy / genetics
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Chromosome Aberrations. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Gene Duplication. Histone-Lysine N-Methyltransferase. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kidney Neoplasms / drug therapy. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Male. Middle Aged. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722759.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Aggarwal S, Prakhar P, Kohli S, Negi A, Jauhari M, Bhalla S: Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India. J Clin Oncol; 2009 May 20;27(15_suppl):e19566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India.
  • The type of NHL was B-Cell type (CD-20+ve) in 132(85%) and T-Cell type (CD 3+ve) in 22 (15%) cases.
  • Out of 77 extra-nodal cases, 31(20%) were GIT NHL (Stomach -16, Colon-8, Ileum-4, and Duodenum-3) and out of the rest 46 extra-nodal cases the site of origin was - head & neck-14, skin n soft tissues -8, primary CNS-6, testicular-4, para-spinal- 3, breast mass-3, perinephric-2, bones-2 and 1 each in cervix, lung mass, liver and cervical plexus.
  • 28 out of 31 were B-Cell type and 3 were T-Cell type.
  • 26 out of 31 were diffuse large cell variety, 2 were mixed small & large cell variety and 1 MALT variety.
  • In 2 patients the type of lymphoma could not be ascertained.
  • Bone marrow infiltration was present in 2 out of 31 cases of GIT Lymphoma.
  • No surgery was performed in patients with stomach lymphoma.
  • RESULTS: Of all the extra-nodal cases chemotherapy was given to 39 patients - R-CHOP = 20 patients, CHOP = 13 patients, high dose MTX in primary CNS NHL = 6 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lerner RE, Weisdorf DJ, Miller JS, McGlave PB, Burns LJ: The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse. J Clin Oncol; 2004 Jul 15;22(14_suppl):6661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse.
  • : 6661 Background: Autologous stem cell transplantation (ASCT) has become the standard treatment for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) responding to conventional salvage chemotherapy.
  • The international prognostic index (IPI) was developed to identify patients with aggressive NHL who have different risks for death.
  • METHODS: Eighty patients, median age 47 years (range 19-68 years), with aggressive NHL (diffuse small, mixed, and large cell, immunoblastic, and anaplastic B-cell) in second complete remission (CR, n = 50) or first chemosensitive relapse (n = 30) were treated between 1984 and 2002 with ASCT.
  • With a median follow-up of 5 years (range 205 days to 14 years), OS and PFS at 5 years were 37% (95% CI 26-48) and 37% (95% CI 26-48), respectively.
  • The high-risk group (3, 4, or 5 IPI factors) had 3.2 times (95% CI 1.5-6.6, p = .002) the risk of death and 3.5 times (95% CI 1.6-7.3, p = .001) the risk of relapse as the low-risk group (0, 1, or 2 IPI factors).
  • Patients with high-risk IPI status at relapse should be considered for novel therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Liu C, DeNardo G, Tobin E, DeNardo S: Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm; 2004 Oct;19(5):545-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
  • AIM: Anti-HLA-DR and anti-CD20 monoclonal antibodies (MAbs) have been effective for immunotherapy and radioimmunotherapy in non-Hodgkin's lymphoma (NHL).
  • The aim of our study was to compare the antilymphoma effects of Lym-1 and rituximab in human lymphoma cell lines, using assays of viability, apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC), under conditions relevant to the clinic.
  • METHODS: To characterize response relationships at varied concentrations of Lym-1 and rituximab, growth inhibition and cell death were assayed over 96 hours in four NHL cell lines derived from Burkitt's or large-cell lymphoma patients.
  • Lym-1 had a substantial, and statistically greater, effect than rituximab over longer intervals of time.
  • Lym-1-induced apoptosis was greater than that of rituximab in all cell lines tested.
  • Lym-1, both the chimeric form and the mouse parent, mediate ADCC more effectively, in the presence of a total peripheral blood leukocyte (PBL) population, than does rituximab, although the results for CDC activity were mixed.
  • CONCLUSIONS: In conclusion, Lym-1 had more potent direct and indirect cytotoxic effects than rituximab in lymphoma cells under conditions achievable in patients.
  • Because the HLA-DR target antigen of Lym-1 is enriched on most B-cell lymphomas, these results support its complementary use in patients as an alternative to CD20 for monoimmunotherapy and for combination immunotherapy with rituximab, because the HLA-DR and CD20 antigens are physically and functionally coupled on human B cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. HLA-DR Antigens / immunology. Immunotherapy / methods. Lymphoma / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Apoptosis. Blotting, Western. Burkitt Lymphoma / drug therapy. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation. Cell Survival. Complement System Proteins. Dose-Response Relationship, Drug. Enzyme Activation. Humans. Leukocytes / cytology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Rituximab. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650447.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 47829
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / HLA-DR Antigens; 0 / Lym-1 monoclonal antibody; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


16. Widder S, Pasieka JL: Primary thyroid lymphomas. Curr Treat Options Oncol; 2004 Aug;5(4):307-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thyroid lymphomas.
  • Primary thyroid lymphoma is a rare disease that continues to produce diagnostic and therapeutic dilemmas.
  • There was great difficulty in distinguishing thyroid lymphoma from anaplastic thyroid carcinoma but, because of new immunocytochemical staining techniques and increased cytopathologic knowledge, our ability to diagnose thyroid lymphoma has improved drastically over the past decade.
  • Surgery that was once the mainstay of treatment for this disease, now plays a minimal role.
  • Current treatment regimens for primary thyroid lymphoma consist of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and external beam radiation.
  • The overall and distant relapse rates have been shown to be significantly lower in those patients receiving combined modality therapy compared to chemotherapy or radiation alone.
  • Although the role of surgery has changed over time, it continues to play an important role, especially in confirming diagnoses through open biopsies, potentially providing local control in the more indolent subtypes, and may play a role in the palliation of symptoms for large obstructive lymphomas.
  • The evolving classification of extranodal lymphomas has brought about a better understanding of the biologic behavior of these tumors.
  • Most thyroid lymphomas are B-cell origin, with six different histologic subtypes, but there appears to be two distinct clinical and prognostic groupings of these rare tumors.
  • The more indolent lymphomas are the subgroup of mucosa-associated lymphoid tissue (MALT) lymphomas comprising approximately 6% to 27% of thyroid lymphomas.
  • This subgroup, when localized to the thyroid (stage IE), responds well to total thyroidectomy or radiation with a complete response rate of more than 90%, leading some authors to recommend surgery as primary therapy in the treatment of localized MALT lymphomas.
  • Therefore, surgery as a primary treatment for thyroid lymphomas would only be recommended under ideal conditions, such as MALT subtype stage IE only, and completely resectable with minimal morbidity.
  • The more common subtype, comprising up to 70% of cases, is diffuse large B-cell lymphoma.
  • Up to 40% of all diffuse large cell lymphomas appear to have undergone transformation from a MALT lymphoma, but they behave in a similar fashion to diffuse large cell lymphomas.
  • Treatment for these tumors should include chemotherapy and radiation.
  • Surgery is rarely beneficial in diffuse large cell lymphoma and the mixed large cell subtypes because the disease is generally disseminated and surgical excision of all disease is not possible or associated with increased morbidity.
  • However, there may be a role for palliative surgical debulking to alleviate obstructive symptoms while the patient is undergoing standard chemotherapy and radiation.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Clinical Trials as Topic. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Radiotherapy, High-Energy / methods. Risk Assessment. Survival Analysis. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Feb;107(2):149-54 [9486910.001]
  • [Cites] Cytopathology. 2001 Aug;12(4):257-63 [11488875.001]
  • [Cites] Eur J Surg. 2002;168(10):572-4 [12666700.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1206-9 [10199754.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):338-41 [11352307.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Int J Mol Med. 2002 Jul;10(1):113-7 [12060861.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Br J Surg. 1980 Jul;67(7):475-7 [7417748.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Br J Surg. 1976 Apr;63(4):253-8 [1276656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1807-12 [2428787.001]
  • [Cites] Curr Treat Options Oncol. 2003 Aug;4(4):269-79 [12943607.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):298-302 [11923138.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Cancer. 1999 Dec 25;87(6):325-45 [10603186.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):200-6 [8275426.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Neth J Med. 1998 Feb;52(2):75-8 [9557530.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2741-5 [12842999.001]
  • [Cites] World J Surg. 2000 Aug;24(8):966-70 [10865042.001]
  • [Cites] J Laryngol Otol. 2001 Nov;115(11):935-7 [11779317.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):907-11 [12417514.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):189-96 [9659258.001]
  • [Cites] Radiology. 1989 May;171(2):439-43 [2649921.001]
  • (PMID = 15233907.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


17. Sahoo S, Hart J: Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis; 2003 Aug;23(3):295-9
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the histopathological changes of liver in four patients who developed hepatomegaly and abnormal liver chemistry tests 2 to 20 days following administration of L-asparaginase as a part of a combination chemotherapy regimen for treatment of acute lymphoblastic leukemia.
  • One patient developed acute fulminant hepatic failure and required liver transplantation.
  • The most consistent pathological change, observed in all four cases, was diffuse steatosis.
  • Other changes included patchy hepatocyte necrosis, mixed inflammatory cell infiltrates in the portal tracts, and variable degrees of hepatocellular, or canalicular cholestasis, or a combination of these.
  • [MeSH-major] Asparaginase / adverse effects. Drug-Induced Liver Injury. Liver Diseases / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Child. Drug Therapy, Combination. Female. Humans. Infant. Liver / pathology. Liver Failure, Acute / chemically induced. Liver Failure, Acute / pathology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14523682.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


18. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL: Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol; 2000 May;24(5):623-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.
  • We report a retrospective clinicopathologic study of 108 primary thyroid gland lymphomas (PTLs), classified using the REAL and proposed WHO classification schemes.
  • All patients presented with a thyroid mass.
  • The PTLs were classified as marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MZBL (n = 30), diffuse large B-cell lymphoma (DLBCL) with MZBL (n = 36), DLBCL without MZBL (n = 41), and follicle center lymphoma (FCL; n = 1).
  • Excluding the FCL, features of lymphomas of MALT-type were identified in all groups, despite a follicular architecture in 23% of cases.
  • Lymphocytic thyroiditis (LT) was identified in 94%.
  • Ninety-one percent of patients presented with stage IE or IIE disease, whereas 69% had perithyroidal soft tissue infiltration.
  • All patients were treated with surgical excision followed by adjuvant therapy (76%): chemotherapy (15%), radiation (19%), or a combination of radiation and chemotherapy (42%).
  • Statistically, stages greater than IE, presence of DLBCL, rapid clinical growth, abundant apoptosis, presence of vascular invasion, high mitotic rate, and infiltration of the perithyroidal soft tissue were significantly associated with death with disease.
  • In summary, PTLs typically occur in middle- to older-aged individuals as a thyroid mass, with a predilection for females.
  • Despite their histologic heterogeneity and frequent simulation of other lymphoma subtypes, virtually all PTLs are lymphomas of MALT-type arising in the setting of LT.
  • Mixed DLBCL and MZBL are common.
  • Overall, PTLs have a favorable outcome with appropriate therapy, but prognosis depends on both clinical stage and histology.
  • MZBL and stage IE tumors have an excellent prognosis, whereas tumors with a large cell component or DLBCL or stage greater than IE have the greatest potential for a poor outcome.
  • [MeSH-major] Lymphoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800981.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST: Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol; 2009 May;88(5):417-24
Genetic Alliance. consumer health - Gastric Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
  • Gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL) show a spectrum of disease characterized by varying proportions of low-grade and high-grade components.
  • While the natural history and optimum treatment for low-grade gastric MALT lymphoma and DLBCL is well established, the prognosis and optimal treatment of patients with both low- and high-grade components is not well established.
  • The purpose of our study was to evaluate the clinical characteristics, survival outcomes, and prognostic factors of patients with gastric MALT lymphoma and gastric DLBCL.
  • A retrospective review of patients with gastric MALT lymphoma, gastric DLBCL, or MALT lymphoma with a high-grade component treated at our centers from 1994 to 2006 was performed.
  • Patients were divided into three categories: "pure MALT lymphoma," "MALT lymphoma with high-grade component" (mixed), and "pure DLBCL."
  • Seventy-six patients were included in our study-26 with pure MALT, 22 with MALT with high-grade component ("mixed"), and 28 with pure DLBCL.
  • Pure MALT lymphoma and mixed lymphoma patients had similar clinical characteristics, whereas pure DLBCL patients had less favorable disease characteristics with significantly poorer performance status, higher number of extranodal sites of disease, higher stage, and larger proportion of bone marrow involvement and international prognostic index (IPI) scores compared with mixed lymphoma.
  • The majority of mixed lymphoma (72.7%) and DLBCL patients (71.4%) were treated with chemotherapy.
  • Of patients receiving chemotherapy, a higher proportion of mixed lymphoma and DLBCL patients received anthracycline-based combination chemotherapy regimens compared with MALT lymphoma (73% vs 71% vs 8%) whereas the proportion of mixed lymphoma and DLBCL patients was similar (p = 0.919).
  • The 5-year overall survival was 78% for MALT lymphoma, 84% for mixed lymphoma, and 45% for DLBCL.
  • On multivariate analysis, DLBCL histology remained significantly prognostic for inferior survival, independent of chemotherapy regimen (hazard ratio (HR) 6.66, 95% confidence interval (CI) 2.01-21.41, p = 0.001).
  • Mixed histology was not prognostic for inferior survival (HR 1.13, 95% CI 0.28-4.54, p = 0.868).
  • Other factors prognostic for inferior survival were serum albumin <37 g/L (HR 3.22, 95% CI 1.11-13.22, p = 0.034) and treatment with non-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (HR 4.89, 95% CI 1.67-14.36, p = 0.004).
  • In conclusion, the clinical characteristics of mixed histology MALT lymphoma are similar to low-grade MALT lymphoma and significantly different from pure DLBCL.
  • The prognosis of mixed histology MALT lymphoma is significantly better than pure DLBCL, independent of IPI and chemotherapy regimen, and pure DLBCL histology is independently prognostic of inferior survival outcome.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / blood. Bone Marrow Neoplasms. Follow-Up Studies. Histological Techniques. Humans. L-Lactate Dehydrogenase / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Serum Albumin / analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777110.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


20. Ohye H, Fukata S, Hirokawa M: [Malignant lymphoma of the thyroid]. Nihon Rinsho; 2007 Nov;65(11):2092-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the thyroid].
  • Primary malignant lymphoma of thyroid is frequently associated with Hashimoto's thyroiditis and it is usually non-Hodgkin type.
  • Thyroid lymphoma is common in women and the mean age at onset is 60 years old.
  • The majority of histopathologic types are extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, diffuse large B-cell lymphoma, and mixed type of above two.
  • If the findings on ultrasonography and fine needle aspiration cytology are suspected thyroid lymphoma, histopathological diagnosis of tissue obtaining from open biopsy is necessary.
  • The treatment for thyroid lymphoma consists of chemotherapy (CHOP), rituximab combined with CHOP, and radiation therapy.
  • It is selected based on the histopathologic type and the extent of disease.
  • The prognosis depends on the histopathologic type and the staging.
  • It should be recognized that early diagnosis and correct treatment lead to favorable prognosis.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Non-Hodgkin. Thyroid Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Hashimoto Disease / complications. Humans. Middle Aged. Molecular Diagnostic Techniques. Neoplasm Staging. Prednisolone / administration & dosage. Prognosis. Radiotherapy. Rituximab. Ultrasonography. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018576.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 15
  •  go-up   go-down


21. Lin TS, Copelan EA: Autologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep; 2003 Jul;2(4):310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for non-Hodgkin's lymphoma.
  • Autologous stem cell transplantation (ASCT) is the only curative option for many patients with relapsed or refractory non-Hodgkin's lymphoma.
  • ASCT achieves long-term survival in up to 50% of patients with chemotherapy-sensitive relapsed diffuse large cell lymphoma (DLCL), and prospective randomized studies have documented the superiority of ASCT over salvage chemotherapy in patients with relapsed DLCL However, the role of ASCT as an upfront therapy for patients with high-risk DLCL remains unclear, and prospective randomized studies have yielded mixed results.
  • In addition, ASCT may not be curative in follicle center or mantle cell lymphoma, although longer follow-up may identify a subset of patients with prolonged survival.
  • Ongoing clinical trials are studying the use of monoclonal antibodies, such as rituximab and iodine 131I-tositumomab, in ASCT regimens to purge tumor cells in vivo and improve long-term outcome in follicle center and mantle cell lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Lymphoma, Follicular / mortality. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / therapy. Salvage Therapy. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12901328.001).
  • [ISSN] 1540-3408
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 36
  •  go-up   go-down


22. Matsubayashi H, Takagaki S, Otsubo T, Iiri T, Kobayashi Y, Yokota T, Shichijo K, Iwafuchi M, Kijima H: Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor. J Gastroenterol; 2002;37(10):863-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor.
  • Abdominal computed tomography (CT) scan and ultrasonography showed enlargement of the whole pancreas with para-aortic lymphadenopathy.
  • Endoscopic retrograde pancreatography (ERP) showed diffuse narrowing of the main pancreatic duct (MPD), and brushing cytology from the MPD was non-neoplastic.
  • Differential diagnosis between lymphoma and other exocrine and endocrine pancreatic malignancies was needed, and the level of serum soluble interleukin-2 receptor (17 751 U/ml) was revealed to be significantly high, which was strongly suggestive of pancreatic lymphoma.
  • Chemotherapy was refused by the patient's family and the patient succumbed after 2 months of conservative follow-up.
  • Autopsy revealed diffuse, mixed cell-type, non-Hodgkin's lymphoma of T-cell subtype.
  • [MeSH-major] Biomarkers, Tumor / blood. Lymphoma, T-Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Receptors, Interleukin-2 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424573.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


23. Porcaro AB, D'Amico A, Novella G, Curti P, Ficarra V, Antoniolli SZ, Martignoni G, Matteo B, Malossini G: Primary lymphoma of the kidney. Report of a case and update of the literature. Arch Ital Urol Androl; 2002 Mar;74(1):44-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the kidney. Report of a case and update of the literature.
  • OBJECTIVES: To report on a case of primary renal lymphoma (PRL) and update the literature concerning this topic.
  • MATERIALS AND METHODS: A 48-year-old woman underwent surgery for the presumed diagnosis of renal cell carcinoma with bilateral adrenal metastases.
  • RESULTS: The neoplasm was assessed as primary renal non-Hodgkin high grade lymphoma, diffuse large B-cell type.
  • Unfortunately, 5 weeks later the patient was lost since missing chemotherapy and follow-up.
  • Several histogenetic theories of the disease have been postulated since the kidney does not normally contain lymphoid tissue.
  • Investigators reported many classes of non-Hodgkin lymphoma which include large, small, intermediate and mixed cell types with high, intermediate or low grade histologies.
  • The neoplastic lymphoid cells may express both B and T immunoblastic phenotypes, primary renal Hodgkin lymphoma has also been reported.
  • The disease may present with progressive renal failure of either oliguric or non oliguric type.
  • Imaging studies in diagnosing and staging primary renal lymphomas include ultrasound examination (US) and computed tomography (CT); there are also some reports of magnetic resonance imaging (MRI).
  • Up to now, there are no standard treatment modalities for this entity since the small number of cases reported.
  • Multidrug chemotherapy is mandatory for high grade lymphoma and when the disease is diagnosed preoperatively.
  • High dose chemotherapy in the future may offer a curative approach in primary bilateral renal disease and without end-stage renal disease.
  • Prognosis may be improved by early detection of disease and by performing systemic chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053451.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 33
  •  go-up   go-down


24. Brousse C, Baumelou E, Morel P: Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine; 2000;67(5):446-51
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone: a prospective study of 28 cases.
  • PURPOSE: To conduct a prospective study of primary lymphoma of bone (PLB) comparatively with extraskeletal non-Hodgkin's lymphomas (ESNHLs) and secondary lymphoma of bone (SLB).
  • PATIENTS AND METHODS: The 28 cases of PLB, 2932 cases of ESNHL, and 219 cases of SLB included between April 1, 1993, and October 1, 1997, in a treatment protocol for NHL developed by the Adult Lymphoma Study Group, were studied prospectively.
  • In the PLB group, 54% of patients had diffuse large cell tumors and 11% diffuse mixed tumors; in the ESNHL group, 39% had diffuse large cell, 13% diffuse mixed, and 8% diffuse immunoblastic tumors; and in the SLB group, 45% had diffuse large cell, 10% diffuse mixed, and 12% diffuse immunoblastic tumors.
  • A complete or partial response to induction therapy was noted in 86% of PLB patients, 84% of ESNHL patients, and 78% of SLB patients.
  • Further studies are needed to determine the effect of radiation therapy at completion of the treatment protocol and to look for prognostic factors associated with bone involvement.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143912.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


28. Parvez T, Behani A, Ali A: Primary gastric lymphoma. J Coll Physicians Surg Pak; 2007 Jan;17(1):36-40
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma.
  • OBJECTIVE: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA).
  • PATIENTS AND METHODS: Case records of 22 patients with a histologically-confirmed diagnosis of PGL were analyzed.
  • According to the treatment modality, different groups were established.
  • Any other histopathological type was excluded from the study.
  • RESULTS: All cases were Non-Hodgkin Lymphoma (NHL).
  • The peak age was in the sixth decades with a slight male preponderance.
  • Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%).
  • Sixteen (73%) patients underwent chemotherapy with some surgical resection, in 5 (23%) surgical procedure was palliative bypass and 11 (50%) had partial gastrectomy.
  • Three (14%) had only chemotherapy after endoscopic biopsy.
  • CONCLUSION: PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II.
  • Chemotherapy after sub-total gastrectomy or biopsy was the best treatment option.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Saudi Arabia. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204218.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Cohen Y, Amir G, Schibi G, Amariglio N, Polliack A: Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis. Eur J Haematol; 2004 Aug;73(2):134-8
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis.
  • Here we present a 40-yr-old male patient with an aggressive B-cell lymphoma, who presented 2 yr earlier with polyarthritis, and was responsive to steroids and oral methotrexate.
  • Thereafter he developed skin and lung lesions which on biopsy consisted of mixed 'inflammatory' infiltrates with granulomatous vasculitis.
  • The patient was now completely asymptomatic for 1 yr, but then generalized lymphadenopathy appeared, which was shown by histopathology to be large B-cell lymphoma, also involving the bone marrow.
  • Despite intensive chemotherapy, his disease could not be controlled because of primary chemoresistance, which was perhaps in some way related to exposure to the suboptimal doses of chemotherapy given during the 'inflammatory' period before the diagnosis of lymphoma was established.
  • It also shows the possible risk of 'masking' a true lymphoma by treating non-malignant diseases with immunosuppressive agents, which may eventually contribute to the development of chemoresistant lymphoma.
  • [MeSH-major] Granulomatosis with Polyangiitis / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Biopsy. Complementarity Determining Regions / genetics. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Disease Progression. Drug Resistance, Neoplasm / drug effects. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Male. Prednisone / adverse effects. Prednisone / therapeutic use


30. Akiyama N, Ohtake H, Ohwada A, Kajiwara K, Hayama M, Kohri M, Taira M, Niitsu N, Horie R, Higashihara M: [Successful radiotherapy for the thoracic cord infiltration of adult T-cell leukemia/lymphoma]. Rinsho Ketsueki; 2003 Nov;44(11):1095-100
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful radiotherapy for the thoracic cord infiltration of adult T-cell leukemia/lymphoma].
  • A-51-year-old woman with a sixteen-year history of mixed connective tissue disease was admitted to the Kitasato University Hospital because of hypogastric pain in September 1999.
  • Colonofiberscopy and computed tomography in the abdomen demonstrated thickening of the intestinal wall with a hemorrhagic ulcer in the terminal ileum.
  • The histopathologic findings of the lesion revealed diffuse infiltration of atypical T-lymphocytes.
  • The diagnosis of adult T-cell leukemia/lymphoma (ATLL) infiltrating the terminal ileum was made.
  • Combination chemotherapy including VEPA-M was undertaken, and resulted in a partial response.
  • T2-weighed MRCT images demonstrated that a lesion with a high intensity signal was present in the spinal cord around Th 7.
  • Administration of intrathecal methotrexate and prednisolone, systemic dexamethasone and local irradiation of 30 Gy improved the paralysis and the abnormal MRCT findings.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Leukemic Infiltration / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Middle Aged. Prednisolone / administration & dosage. Spinal Cord / pathology. Thorax

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14689874.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Xu RH, Jiang WQ, Li YH, Lin TY, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ: [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]. Zhonghua Yi Xue Za Zhi; 2003 Feb 10;83(3):191-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases].
  • OBJECTIVE: To analyze the curative effect of aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis.
  • METHODS: The curative effects of aggressive non-Hodgkin's lymphoma which were diagnosed as diffuse small cleaved (E), diffuse mixed (F), diffuse large cell (G) or diffuse immunoblastic lymphoma (H) pathologically and certified as B cell lymphoma immunohistologically and treated with CHOP or other ADM-containing regimens for at least 4 cycles from 1993 to 1997 were analyzed.
  • CONCLUSION: The treatment with CHOP as its main component has a beneficial effect on aggressive B cell lymphoma in low risk group, but is less effective for the low-intermediate, high-intermediate, and high risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Follow-Up Studies. Humans. Infant. Middle Aged. Prednisone / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12812658.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • The patient, a 63-year-old man had a large tumor in the head of the pancreas, without obstructive jaundice.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Dupire S, Coiffier B: Targeted treatment and new agents in diffuse large B cell lymphoma. Int J Hematol; 2010 Jul;92(1):12-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted treatment and new agents in diffuse large B cell lymphoma.
  • The outcome of patients with diffuse large B cell lymphoma (DLBCL) has completely changed with the introduction of rituximab in combination with chemotherapy.
  • This was the first targeted therapy, and it led the way to new antibodies targeting cell surface receptors and to small molecules targeting one or several key proteins of the cellular machinery.
  • Those new therapeutic small molecules are targeting the different pathways of apoptosis, proteasome inhibitors, immunomodulators, histone deacetylase inhibitors, mammalian target of rapamycin inhibitors, heat shock protein inhibitors, PKC inhibitors, antiangiogenic agents, Syk inhibitors, and farnesyl transferase inhibitors.
  • Although the majority of them have been studied in mixed subtypes of B cell lymphoma, the aim of this review was to present major results in clinical studies for these new agents in DLBCL patients, and for those that have just entered clinical evaluation, the results of pre-clinical studies in DLBCL lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems / methods. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Humans. Treatment Outcome


36. Kuyama A, Takeuchi M, Munemasa M, Tsutsui K, Aga N, Goda Y, Kanetada K: Successful treatment of primary adrenal non-Hodgkin's lymphoma associated with adrenal insufficiency. Leuk Lymphoma; 2000 Jun;38(1-2):203-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary adrenal non-Hodgkin's lymphoma associated with adrenal insufficiency.
  • We report a case of primary adrenal NHL associated with adrenal insufficiency which was successfully treated with steroid replacement and chemotherapy.
  • A 69-year-old woman hospitalized with fatigue and weight loss developed shock and recovered with steroid therapy.
  • Computed tomography revealed large bilateral adrenal masses.
  • Needle biopsy showed a diffuse, mixed B cell lymphoma.
  • CHOP therapy accompanied by steroid replacement was begun, and she achieved a complete remission after 4 cycles.
  • She received additional 4 cycles of chemotherapy.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Steroids / therapeutic use
  • [MeSH-minor] Adrenal Insufficiency / drug therapy. Adrenal Insufficiency / pathology. Adrenal Insufficiency / physiopathology. Aged. Drug Therapy, Combination. Female. Humans

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811465.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Steroids
  •  go-up   go-down


37. Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, Maclennan KA, Vaughan B, Vaughan G, Gregory WM: A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol; 2000;11 Suppl 1:87-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
  • BACKGROUND: Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen.
  • PATIENTS AND METHODS: Four hundred fifty-nine eligible patients were included in this trial, four hundred one with diffuse large-cell lymphoma and fifty-eight with diffuse mixed-cell lymphoma according to the Working Formulation.

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707786.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


38. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


39. Ogasawara T, Yasuyama M, Kawauchi K: [Biclonal light chain gammopathy in multiple myeloma--a case report]. Nihon Rinsho Meneki Gakkai Kaishi; 2002 Apr;25(2):170-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1990, she had a chemotherapy for diffuse mixed cell lymphoma.
  • She eventually developed angioimmunoblastic T-cell lymphoma.
  • Biclonal gammopathy associated with malignant lymphoma is rare in case of multiple myeloma and may provide some insight into the pathogenesis of plasma cell tumors.
  • [MeSH-minor] Aged. Female. Humans. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / immunology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043184.001).
  • [ISSN] 0911-4300
  • [Journal-full-title] Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • [ISO-abbreviation] Nihon Rinsho Meneki Gakkai Kaishi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


40. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A: [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. Bull Cancer; 2007 Oct;94(10):902-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
  • [Transliterated title] Caractéristiques thérapeutiques et évolutives des lymphomes folliculaires du Noir africain: expérience de la Côte d'Ivoire.
  • We reported in this study a treatment results about 36 Africans patients with follicular lymphoma.
  • The average age of patients was 18 to 73 years old with a median age at 50.83 years old and a sex ratio of 1.
  • Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27.78 and 22.22%.
  • Using varieties of therapeutics regiments, we obtained 41.67% of complete remission.
  • Indeed, the follicular lymphomas constituted by large cells and mixed cells had higher rate of complete remission with respectively 46.67% and 40% in relation with those of small cells with a higher failure rate.
  • After a long period, 25 cases of death have been reported, 5 cases of losing sight and 6 patients are still alive and following treatment.
  • The short survival delay time of our patients didn't permit time to observe transformation case in diffuse large cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cote d'Ivoire. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964984.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP-B protocol; COP protocol 2
  •  go-up   go-down


41. Jezersek Novaković B, Vovk M, Juznic Setina T: A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. Ann Hematol; 2006 Dec;85(12):849-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
  • Primary gastric lymphomas are the most common extranodal non-Hodgkin's lymphomas and are divided into indolent (low grade) and aggressive (high grade) types.
  • They are mainly the disease of middle age, with a male predominance reported by most of the studies.
  • For several years, surgery played a central role in diagnosis, staging, and treatment of this entity, yet recently there has been a move away from a surgical approach to conservative treatment.
  • To determine the role of surgery as the initial treatment modality, we performed this retrospective single-center research on 245 patients with primary gastric lymphoma who were treated according to our protocol between 1990 and 2003.
  • The patients' characteristics, distribution of histological types, treatment results, and disease-specific survival were followed.
  • According to the histology, 59.2% had diffuse large B-cell lymphoma (DLCL), 26.1% MALT lymphoma, 9.8% mixed lymphoma (indolent and aggressive at the same time), while other types were infrequent.
  • In total, 161 patients (65.7%) were treated with surgical resection as the initial treatment, which was then followed or not by additional therapy (chemotherapy, chemotherapy and radiotherapy, radiotherapy) depending on the histological type of lymphoma and the extent of residual disease after surgery.
  • In 84 patients (34.3%), the treatment approach was conservative.
  • The selection of treatment (chemotherapy, chemotherapy and radiotherapy, radiotherapy or Helicobacter pylori eradication only) was based on the histological type of lymphoma, considering also the patients' physical condition.
  • However, the results were biased, as the patients who were treated conservatively were either in a worse performance status or presented with a more extensive disease.
  • Similarly, in the DLCL type the disease-specific survival was better in the surgically treated group (97.2%) than in the conservatively treated patients (89.2%).
  • The difference was barely significant (p=0.046) and again the results have to be considered with caution due to the selection of patients in a worse performance status or with a more extensive disease for conservative treatment.
  • In the MALT lymphoma and mixed lymphoma types, there were no differences in the disease-specific survival between both treatment groups.
  • Regarding the statement that for conservative treatment patients were selected who were unsuitable for the resection on account of concomitant diseases or due to the fact that the process was inoperable, we believe that the conservative approach gives comparable outcomes to the approach including initial surgery.
  • The existing evidence thus no longer justifies surgery as the standard initial treatment and preference should be given to conservative treatment approaches.
  • [MeSH-major] Lymphoma / mortality. Lymphoma / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / pathogenicity. Humans. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944146.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Babovic N, Jelic S, Jovanovic V: Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy? J Exp Clin Cancer Res; 2000 Jun;19(2):149-54
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?
  • Primary lymphoma of the breast is a rare disease that has been estimated to represent from 0.05% to 0.53% of all malignant breast tumors and approximately 2.2% of all extranodal lymphomas.
  • The aim of this study is to review all cases of primary lymphoma of the breast at the Institute of Oncology and Radiology of Serbia from 1984 to 1996 in order to determine the incidence, patterns of clinical presentation, radiological features, histopathology, mode of therapy and outcome of the disease.
  • The clinical histories of ten patients with breast lymphomas were reviewed.
  • Ten cases of primary lymphoma of the breast have been identified during the 12-yr period, presenting 0.05% of all patients with malignant breast disease.
  • Mammography and breast echography were unable to bring a suspicion of lymphoma.
  • Histologically, 6 cases were diffuse large cell, 3 of which with features consistent with immunoblastic lymphoma; 2 were diffuse mixed cells and 2 had small lymphocytic morphology.
  • In 4 out of 5 patients, in the clinical stage corresponding to the "operable breast cancer" category, the ex tempore histological analysis could not differentiate lymphoma from cancer, so that all of them had mastectomy with axillary dissection.
  • Those corresponding to the "locally advanced breast cancer" category, escaped mastectomy and a classical biopsy was performed, anticipating eventual neoadjuvant procedures.
  • Further treatment included chemotherapy for 8 patients.
  • The rarity of this disease, and uneven treatment modalities make prognosis of breast lymphoma difficult.
  • With the limitations of available diagnostic procedures, it appears that most patients with breast lymphoma, in the stage corresponding to the "operable breast cancer" category, will unnecessarily undergo mastectomy and axillary dissection as primary treatment approach.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Mastectomy, Radical
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965810.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


43. Marschalkó M, Eros N, Holló P, Hársing J, Bottlik G, Bátai A, Csukly Z, Masszi T, Szentirmai Z, Fodor J, Kárpáti S, Matolcsy A, Csomor J: Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. Am J Dermatopathol; 2010 Oct;32(7):708-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.
  • At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed.
  • Chemotherapy resulted in complete remission of the lymphadenopathy.
  • Four years later, systemic relapse was detected which was refractory to therapy.
  • Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells.
  • Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644462.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


44. Murase T, Fujita A, Ueno H, Park JW, Yano T, Hoshikawa M, Takagi M, Kuramochi S: A case of age-related EBV-associated B-cell lymphoproliferative disorder metachronously showing two distinct morphologic appearances, one of a polymorphic disease resembling classical Hodgkin lymphoma, and the other of a large-cell lymphoma. Int J Hematol; 2009 Jan;89(1):80-5
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of age-related EBV-associated B-cell lymphoproliferative disorder metachronously showing two distinct morphologic appearances, one of a polymorphic disease resembling classical Hodgkin lymphoma, and the other of a large-cell lymphoma.
  • We report a case of age-related EBV-associated B-cell lymphoproliferative disorder (age-related EBV+ B-cell LPD) metachronously showing two distinct morphologic appearances: one of a polymorphic disease resembling classical Hodgkin lymphoma (CHL), and the other of a large-cell lymphoma.
  • Right axillary lymph node biopsy revealed mixed cellularity classical Hodgkin lymphoma (MCHL).
  • The patient was referred to the Tokyo Medical Center, where he was treated with chemotherapy and obtained CR.
  • One year later, the patient again developed fever and generalized lymphadenopathy.
  • Biopsy of the right cervical mass revealed a diagnosis of diffuse large B-cell lymphoma.
  • Two years later, the patient developed acute myeloid leukemia (AML).
  • Although CR was achieved with chemotherapy, AML relapsed 5 months later and proved to be refractory.
  • Two and a half years later, the patient developed right cervical lymph node enlargement.
  • Both HRS-like cells at the time of diagnosis of Hodgkin lymphoma and lymphoma cells at the time of diagnosis of non-Hodgkin lymphoma were positive for CD20 and EBV-encoded small RNAs.
  • This case was finally diagnosed as having age-related EBV+ B-cell LPD.
  • We report the case here as it underscores the difficulty in diagnosing age-related EBV+ B-cell LPDs and also suggests an important role of EBV in the pathogenesis of lymphoid neoplasms.
  • [MeSH-major] Lymphoma, B-Cell / pathology
  • [MeSH-minor] Aged. Herpesvirus 4, Human. Hodgkin Disease / pathology. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5124-32 [17785567.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):312-25 [8113838.001]
  • [Cites] Pathol Int. 2007 Oct;57(10):688-93 [17803658.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:83-92 [2049324.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] N Engl J Med. 1979 Mar 1;300(9):452-8 [366418.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] Rinsho Ketsueki. 1986 Feb;27(2):252-6 [2425103.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Eur J Immunol. 2000 Feb;30(2):458-69 [10671201.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):510-6 [9178801.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):487-97 [10653864.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2026-32 [11310450.001]
  • [Cites] Arch Intern Med. 1983 Mar;143(3):445-50 [6338848.001]
  • (PMID = 19093168.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


45. Ishibashi M, Yamamoto K, Kudo S, Chen KR: Mantle cell lymphoma with skin invasion characterized by the common variant in the subcutis and blastoid transformation in the overlying dermis. Am J Dermatopathol; 2010 Apr;32(2):180-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma with skin invasion characterized by the common variant in the subcutis and blastoid transformation in the overlying dermis.
  • We report a case of common mantle cell lymphoma (MCL) with subcutis infiltration and transformation to blastoid MCL in the overlying dermis.
  • The patient was initially diagnosed as having chronic lymphocytic leukemia and treated with chemotherapy.
  • Eight months after the diagnosis of MCL with bone marrow involvement, subcutaneous nodules developed on the patient's left thigh and forearm.
  • A skin biopsy showed a massive infiltration of neoplastic lymphocytes throughout the dermis and subcutaneous tissue.
  • In the upper dermis, there was a perivascular mixed infiltrate of atypical large lymphoid cells and small-sized cells.
  • In the mid to lower dermis, the infiltrate was dense with a nodular growth pattern and was composed of atypical large lymphoblast-like cells with large nuclei, dispersed chromatin, and numerous mitoses.
  • In the subcutaneous tissue, there was a diffuse infiltration of neoplastic cells with common MCL cytologic features characterized by small- to medium-sized lymphoid cells.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Dermis / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010283.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 136601-57-5 / Cyclin D1
  •  go-up   go-down


46. Chen HW, Sheu JC, Lin WC, Tsang YM, Liu KL: Primary liver lymphoma in a patient with chronic hepatitis C. J Formos Med Assoc; 2006 Mar;105(3):242-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver lymphoma in a patient with chronic hepatitis C.
  • Primary liver lymphoma is a very rare disease and is frequently overlooked as a possible diagnosis.
  • We report the case of an asymptomatic middle-aged man with chronic hepatitis C who developed primary liver lymphoma (PLL).
  • A large solitary tumor in the left lobe of the liver was incidentally detected on routine ultrasound examination.
  • Imaging studies showed mixed iso- and hypoechogenicity with hypoechoic rim, hypodense in the pre-contrast phase and thick wall enhancement in the post-contrast phase on computed tomographic study, hypointensity on T1WI, and hyperintensity of the central portion and slightly higher intensity in the peripheral wall on T2WI.
  • Atypical hepatectomy was performed and the pathology of the hepatic tumor revealed non-Hodgkin's lymphoma.
  • There was no tumor recurrence more than 4 years after operation and chemotherapy.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520842.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


47. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R: Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer; 2000 Oct 15;89(8):1835-44
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
  • BACKGROUND: Primary cutaneous B-cell lymphoma (CBCL) is characterized by restriction to the skin, a high incidence of recurrence after various treatment modalities, and a variable but mostly favorable prognosis.
  • METHODS: Ten patients with long standing primary CBCL (3 with follicular CBCL, 5 with cutaneous, large B-cell lymphoma, 1 with diffuse large cell lymphoma, and 1 with extranodal large cell lymphoma) were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen that is present on malignant and normal B-cells.
  • In 6 of 10 patients, several treatment attempts either had failed or could not be used due to severe side effects or underlying disease.
  • RESULTS: The treatment regimen resulted in two complete regressions, five partial responses, and one mixed response, and two patients did not respond to the treatment.
  • CONCLUSIONS: Intravenous therapy with the anti-CD20 antibody rituximab is a nontoxic and effective treatment for patients with primary cutaneous B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Rituximab. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11042581.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


48. Wajchman J, Simmons WJ, Klein A, Koneru M, Ponzio NM: Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice. Leuk Res; 2002 Jun;26(6):577-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice.
  • The B cell lymphomas (RCS) that develop spontaneously in 90% of aging SJL/J mice stimulate syngeneic CD4+ Vbeta16+ Th2 cells to produce cytokines, such as IL-4 and IL-5, which promote lymphoma growth.
  • Antibody depletion studies revealed at least two types of RCS/IL-12-induced cytotoxic cells:.
  • Despite high titers of IFN-gamma in the SN of co-culture of SJL spleen and gamma-RCS cells, cytotoxicity only developed if IL-12 was also included in the co-cultures.
  • The results of RNAse protection assays and multi-parameter FACS analysis demonstrated an upregulation of IFN-gamma and decrease in IL-4 by activated Th cells in co-cultures with IL-12.
  • Results of in vivo experiments support this hypothesis, as judged by tumor growth assays and FACS analysis of the tumor cell content of lymphoid tissues.
  • Inhibition of lymphoma growth was observed in mice given gamma-RCS/IL-12-induced effector cells prior to injection of viable RCS cells.
  • These results demonstrate that IL-12 can be used to alter the host immune response leading to induction of cytotoxic effector cells that inhibit the development and/or progressive growth of otherwise resistant B cell lymphomas in SJL/J mice.
  • [MeSH-major] Interleukin-12 / immunology. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Animals. Immunotherapy, Adoptive / methods. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Lymphocyte Culture Test, Mixed. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Mice. Mice, Inbred Strains. Neoplasm Transplantation. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Transplantation, Isogeneic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12007506.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


49. Rozenbaum M, Slobodin G, Boulman N, Feld J, Avshovich N, Ben-Arieh Y, Rosner I: Therapeutic vignette: old and new drugs in mixed connective tissue disease. Isr Med Assoc J; 2008 Nov;10(11):831-2
Hazardous Substances Data Bank. POTASSIUM IODIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vignette: old and new drugs in mixed connective tissue disease.
  • [MeSH-major] Mixed Connective Tissue Disease / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antirheumatic Agents / administration & dosage. Antirheumatic Agents / adverse effects. Comorbidity. Disease Progression. Drug Therapy, Combination. Fatal Outcome. Glucocorticoids / administration & dosage. Humans. Immunosuppressive Agents / administration & dosage. Infliximab. Lymphoma, Large B-Cell, Diffuse / chemically induced. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Potassium Iodide / administration & dosage. Potassium Iodide / therapeutic use. Prednisone / administration & dosage. Skin Ulcer / drug therapy. Skin Ulcer / etiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Vasculitis / etiology

  • Genetic Alliance. consumer health - Mixed connective tissue disease.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070300.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; 1C4QK22F9J / Potassium Iodide; B72HH48FLU / Infliximab; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement